The 47th Annual EASL: Online Expert Poster Review and Discussion

EASL-2012_PosterProgram_WebBanner.jpg 

EASL-2012_PosterProgram_View 

About the Program

Program Overview

This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at EASL. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.  

Back to Top  

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be able to:

  • Recognize and review clinically relevant posters and presentations on chronic hepatitis C made at the 46th EASL; 

  • Explain to colleagues the clinical trials and data presented in the most important posters and presentations on chronic hepatitis C at the 46th EASL;

  • Discuss the scientific integrity and clinical relevance of the most important posters and presentations on chronic hepatitis C at the 46th EASL;

  • Use the information and data presented in the most important posters and presentations at the 46th EASL to improve patient care.

Release Date:  April 30, 2012
Expiration Date: April 30, 2013

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top

Faculty

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York

Paul Y. Kwo, MD 
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana 

Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany

Paul J. Pockros, MD 
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.   

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There will be 10 posters and presentations available for a total of 2.50 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Dr. Douglas Dieterich:

Dr. Douglas Dieterich 

  • Consulting Fees: Gilead; Merck; Vertex; BI; Pharmasset; Idenix

Dr. Paul Kwo:

  • Contracted Research: Anadys; Contus; Merck; Roche; BMS; Gilead; Vertex; Abbott
  • Consulting Fees: Merck; Vertex; BMS; Abbott; Gilead; Novartis; Bohringer Ingelheim; Johnson & Johnson
  • Fees for Non-CME/CE Services: Merck; Roche; BMS; Gilead

Dr. Paul Pockros:

  • Contracted Research: Merch; Genentech; Vertex; Janssen; Gilead; BMS; Contus; BI
  • Consulting Fees: Merck; Contus; Novartis; BI; Vertex; Genentech; Janssen; BMS; Gilead
  • Fees of Non-CME/CE Services: Genentech, Vertex, BMS

Dr. Jurgen Rockstroh:

  • Contracted Research: Abbott; Merck; Roche
  • Consulting Fees: Abbott; Bionor; BMS; Boehringer Ingelheim; Gilead; GSK; Merck; Novartis; Pfizer; Roche; Tibotec; ViiV

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing 

EASL_PosterProgram2012_poster1.jpg

Interferon-Free Treatment With a Combination of Mericitibine and Danoprevir/r With or Without Ribavirin in Treatment-Naive HCV GT1

EASL_PosterProgram2012_48.jpg

Early versus Delayed Treatment of Acute Hepatitis C: Final Results of the Randomized Controlled German HEP-NET Acute HCV-III Study

EASL_PosterProgram2012_7.jpg

PSI-7977 PROTON and ELECTRON: 100% Concordance of SVR4 with SVR24 in HCV GT1, GT2, and GT

EASL_PosterProgram2012_13.jpg A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects
EASL_PosterProgram2012_14.jpg Dual Oral Therapy with the NS5A Inhibitor (BMS-790052) and NS3 PI (BMS-650032) in HCV Genotype 1B-infected Null Responder or Ineligible/Intolerant to Peginterferon/Ribavirin
EASL_PosterProgram2012_47&8.jpg Efficacy and Safety of PIs for Severe HCV Recurrance After Liver Transplantation: A First Multicentric Experience AND Safety of Telaprevir or Boceprevir in Combination with Peginterferon alfa/Ribavirin, in Cirrhotic Non-responders: First Results of the French Early Access Program
EASL_PosterProgram2012_1405.jpg Alisporivir plus Ribovirin is highly effective as Interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12Results from VIRAL-1 Phase 2b Study
EASL_PosterProgram2012_2.jpg Final SVR24 Results of the ASPIRE Trial
EASL_PosterProgram2012_50.jpg Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-infected Patients: End of Treatment (Week 48) Interim Results
EASL_PosterProgram2012_1419.jpg A Randomized Trial Comparing Ribavirin Dose Reduction vs. Erythropoietin for Anemia Management in Previously Untreated Patients with Chronic Hepatitis C Receiving Boceprevir Plus Peginterferon/Ribavirin
Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.   

Back to Top

PIM_small

 Supported by an educational grant from Merck & Co., Inc.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings


Prepare to print

Share this page:

Get link code to this page     


Back to Top